MX2017006473A - Metodos para tratar la esclerosis multiple. - Google Patents

Metodos para tratar la esclerosis multiple.

Info

Publication number
MX2017006473A
MX2017006473A MX2017006473A MX2017006473A MX2017006473A MX 2017006473 A MX2017006473 A MX 2017006473A MX 2017006473 A MX2017006473 A MX 2017006473A MX 2017006473 A MX2017006473 A MX 2017006473A MX 2017006473 A MX2017006473 A MX 2017006473A
Authority
MX
Mexico
Prior art keywords
fumarate
methods
foregoing
multiple sclerosis
treating multiple
Prior art date
Application number
MX2017006473A
Other languages
English (en)
Inventor
Novas Mark
Rui, (ray) ZHANG
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54771192&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017006473(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MX2017006473A publication Critical patent/MX2017006473A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/492—Determining multiple analytes
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
    • G09B19/00—Teaching not covered by other main groups of this subclass
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Se proporcionan en la presente métodos para el tratamiento de la esclerosis múltiple con un fumarato, en donde el fumarato es un fumarato de dialquilo, un fumarato de monoalquilo, una combinación de fumarato de dialquilo y fumarato de monoalquilo, un profármaco de fumarato de monoalquilo, una forma deuterada de cualquiera de los anteriores, o una sal, clatrato, solvato, tautómero o estereoisómero farmacéuticamente aceptable de cualquiera de los anteriores, o una combinación de cualquiera de los anteriores. Los métodos aquí proporcionados mejoran la seguridad del tratamiento al informar y monitorear a los pacientes que se someten a tratamiento con respecto a leucoencefalopatía multifocal progresiva, y/o al monitorear el conteo de linfocitos.
MX2017006473A 2014-11-17 2015-11-16 Metodos para tratar la esclerosis multiple. MX2017006473A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462080783P 2014-11-17 2014-11-17
US201562140255P 2015-03-30 2015-03-30
US201562232963P 2015-09-25 2015-09-25
PCT/US2015/060850 WO2016081355A1 (en) 2014-11-17 2015-11-16 Methods of treating multiple sclerosis

Publications (1)

Publication Number Publication Date
MX2017006473A true MX2017006473A (es) 2018-01-30

Family

ID=54771192

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006473A MX2017006473A (es) 2014-11-17 2015-11-16 Metodos para tratar la esclerosis multiple.

Country Status (13)

Country Link
US (8) US20170354630A1 (es)
EP (3) EP4215191A1 (es)
JP (4) JP6786486B2 (es)
KR (3) KR20240035912A (es)
CN (6) CN113368091A (es)
AU (3) AU2015350213A1 (es)
CA (1) CA2967619C (es)
EA (1) EA038370B1 (es)
IL (2) IL269885B (es)
MA (2) MA40985A (es)
MX (1) MX2017006473A (es)
WO (1) WO2016081355A1 (es)
ZA (1) ZA201703207B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA51730A (fr) 2014-03-14 2020-12-16 Biogen Ma Inc Fumarate de diméthyle et régimes de vaccination
MA40985A (fr) 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques
SG10201907289VA (en) 2015-02-08 2019-09-27 Alkermes Pharma Ireland Ltd Monomethylfumarate prodrug compositions
EP3786171A1 (en) 2016-04-01 2021-03-03 Nohms Technologies, Inc. Modified ionic liquids containing phosphorus
KR102638417B1 (ko) 2017-07-17 2024-02-19 놈스 테크놀로지스, 인크. 인 함유 전해질
WO2020214693A1 (en) * 2019-04-17 2020-10-22 Ixchel Pharma, Llc Prodrugs of monomethyl fumarate
BR112021018452B1 (pt) * 2019-05-31 2022-10-04 Curacle Co., Ltd Comprimido de revestimento entérico e seu método de preparação
CN111440771A (zh) * 2020-03-17 2020-07-24 中山大学附属第三医院 一种含有clcn2纯合突变的白质脑病患者特异诱导多能干细胞系
WO2021144478A2 (en) 2020-05-06 2021-07-22 Imcyse Sa Combination treatment for fumarate-related diseases
KR20220075119A (ko) * 2020-11-27 2022-06-07 주식회사 뷰노 의료 영상 기반의 뇌백질 병변 탐지 방법
KR102566549B1 (ko) * 2021-06-08 2023-08-14 제이투에이치바이오텍 (주) 3성분 프로드럭, 이의 약학적 조성물 및 의약 용도

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959389A (en) 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
DE19721099C2 (de) 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
EP2801354B1 (en) 2004-10-08 2017-02-08 Forward Pharma A/S Controlled release pharmaceutical compositions comprising a fumaric acid ester
EP3620469A1 (en) 2006-02-28 2020-03-11 Biogen MA Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
ES2599227T3 (es) * 2007-02-08 2017-01-31 Biogen Ma Inc. Neuroprotección en enfermedades desmielinizantes
ES2477884T3 (es) 2008-08-19 2014-07-18 Xenoport, Inc. Profármacos de hidrogenofumarato de metilo, composiciones farmacéuticas de los mismos y procedimientos de uso
HRP20221390T1 (hr) 2010-01-11 2023-01-06 Biogen Ma Inc. Analiza za antitijela jc virusa
EP2713724A4 (en) 2011-05-26 2015-03-11 Biogen Idec Inc METHODS OF TREATING MULTIPLE SCLEROSIS AND PRESERVING AND / OR INCREASING MYELINE CONTENT
RS58967B1 (sr) 2011-05-31 2019-08-30 Biogen Ma Inc Metod evaluacije rizika za pml
CN114146080A (zh) 2012-02-07 2022-03-08 比奥根玛公司 含有富马酸二甲酯的药物组合物
WO2014031901A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Methods of use for monomethyl fumarate and prodrugs thereof
WO2014071371A1 (en) 2012-11-05 2014-05-08 Xenoport, Inc. Cocrystals of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate
EP2934507B1 (en) 2012-12-21 2017-05-31 ratiopharm GmbH Prodrugs of monomethyl fumarate (mmf)
TW201436790A (zh) 2012-12-21 2014-10-01 Biogen Idec Inc 經氘取代之反丁烯二酸酯衍生物類
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US20140322252A1 (en) 2013-04-26 2014-10-30 Michael Ruff Peptides for Treating Alzheimers's Disease and Related Conditions
WO2015017762A1 (en) 2013-08-01 2015-02-05 Xenoport, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
EP3766487A1 (en) 2014-02-28 2021-01-20 Banner Life Sciences LLC Controlled release enteric soft capsules of fumarate esters
MA51730A (fr) 2014-03-14 2020-12-16 Biogen Ma Inc Fumarate de diméthyle et régimes de vaccination
CA2962916C (en) 2014-10-08 2021-06-15 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
MA40985A (fr) 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques
WO2017040272A1 (en) 2015-08-31 2017-03-09 Banner Life Sciences Llc Fumarate ester dosage forms
WO2017151184A1 (en) 2016-02-29 2017-09-08 Banner Life Sciences Llc Fumarate ester dosage forms
US10523918B2 (en) 2017-03-24 2019-12-31 Samsung Electronics Co., Ltd. System and method for depth map

Also Published As

Publication number Publication date
CN113368091A (zh) 2021-09-10
US11129806B2 (en) 2021-09-28
NZ731528A (en) 2021-11-26
CN113368093A (zh) 2021-09-10
US20170368013A1 (en) 2017-12-28
MA40985A (fr) 2017-09-26
US20180000770A1 (en) 2018-01-04
CA2967619A1 (en) 2016-05-26
CN115531366A (zh) 2022-12-30
AU2015350213A1 (en) 2017-05-25
US20200345679A1 (en) 2020-11-05
US20190125710A1 (en) 2019-05-02
US20210023040A1 (en) 2021-01-28
US11246850B2 (en) 2022-02-15
US20210315854A1 (en) 2021-10-14
US10959972B2 (en) 2021-03-30
US11007167B2 (en) 2021-05-18
JP6830941B2 (ja) 2021-02-17
EA038370B1 (ru) 2021-08-17
WO2016081355A1 (en) 2016-05-26
KR20210111362A (ko) 2021-09-10
CN115501218A (zh) 2022-12-23
US11007166B2 (en) 2021-05-18
MA53882A (fr) 2021-12-08
JP6786486B2 (ja) 2020-11-18
AU2021269298A1 (en) 2021-12-09
EP3804711A1 (en) 2021-04-14
US20170354630A1 (en) 2017-12-14
US20190008817A1 (en) 2019-01-10
KR20170084270A (ko) 2017-07-19
JP2020196760A (ja) 2020-12-10
JP2017537089A (ja) 2017-12-14
EA201791101A1 (ru) 2017-12-29
EP4215191A1 (en) 2023-07-26
KR102299842B1 (ko) 2021-09-09
IL269885B (en) 2022-06-01
KR20240035912A (ko) 2024-03-18
IL252296B (en) 2022-06-01
IL252296A0 (en) 2017-07-31
JP2022168243A (ja) 2022-11-04
CN107106530A (zh) 2017-08-29
EP3220907A1 (en) 2017-09-27
CN113368092A (zh) 2021-09-10
JP2019023248A (ja) 2019-02-14
CA2967619C (en) 2022-06-28
AU2020239734A1 (en) 2020-10-15
ZA201703207B (en) 2021-08-25

Similar Documents

Publication Publication Date Title
MX2017006473A (es) Metodos para tratar la esclerosis multiple.
IL283561B (en) Methods for treating eye diseases
IL288712B1 (en) Methods for treating abnormal movement disorders
HK1231417A1 (zh) 用於治療眼科疾病和障礙的化合物
TW201613872A (en) IRAK4 inhibiting agents
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
ZA201700416B (en) Methods for treating or preventing ophthalmological conditions
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
HK1257240A1 (zh) 預防和治療脂肪異常沉積導致的組織損傷的藥物及其用途
NZ730816A (en) Quinoline carboxamides for use in the treatment of multiple myeloma
MY183209A (en) Heterocyclic compound
PL3129483T3 (pl) Terapia skojarzona do leczenia chorób autoimmunologicznych
MY198753A (en) Treatment of androgen deprivation therapy associated symptoms
EA202191097A1 (ru) Способы лечения рассеянного склероза
IL259381B (en) Miravegron for the treatment of retinal diseases
NZ747201A (en) (+)-azasetron for use in the treatment of ear disorders
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases
UA90546U (uk) Спосіб лікування хворих на дисциркуляторну енцефалопатію